Cost-containment as part of pharmaceutical policy

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Cost-containment as part of pharmaceutical policy. / Almarsdóttir, Anna Birna; Traulsen, Janine M.

In: International Journal of Clinical Pharmacy, Vol. 27, No. 3, 06.2005, p. 144-8.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Almarsdóttir, AB & Traulsen, JM 2005, 'Cost-containment as part of pharmaceutical policy', International Journal of Clinical Pharmacy, vol. 27, no. 3, pp. 144-8. https://doi.org/10.1007/s11096-005-6953-6

APA

Almarsdóttir, A. B., & Traulsen, J. M. (2005). Cost-containment as part of pharmaceutical policy. International Journal of Clinical Pharmacy, 27(3), 144-8. https://doi.org/10.1007/s11096-005-6953-6

Vancouver

Almarsdóttir AB, Traulsen JM. Cost-containment as part of pharmaceutical policy. International Journal of Clinical Pharmacy. 2005 Jun;27(3):144-8. https://doi.org/10.1007/s11096-005-6953-6

Author

Almarsdóttir, Anna Birna ; Traulsen, Janine M. / Cost-containment as part of pharmaceutical policy. In: International Journal of Clinical Pharmacy. 2005 ; Vol. 27, No. 3. pp. 144-8.

Bibtex

@article{3545a7e185374501ab610d84693d3cae,
title = "Cost-containment as part of pharmaceutical policy",
abstract = "In this article the authors provide insight into the basis for price setting of medicines, the increasing pharmaceutical budgets in the past decades, and the measures governments and insures have taken to curb rising pharmaceutical costs. Four reasons are out lined for the fact that medicines are by some considered expensivey: 1) there are fundamental differences between medicines and other consumer products; 2) medicines are technology requiring an inordinate amount of research and development; 3) medicines are developed, manufactured, and distributed according to strict regulatory requirements; 4) medicines are most often selected by a physician for a specific patient and reimbursed in whole or in party by a third-party insurer or the state. Pharmaceuticals mean share of GDP has been 1.2{\%} in OECD countries in recent decades. Pharmaceuticals accounted for 15.4{\%} of total health expenditure, with public spending about half of this amount. Since 1970, the average share of GDP for pharmaceuticals in most countries has increased 1.5{\%} more per year than GDP growth. Four types of strategies to curb rising Pharmaceuticals costs are described and a taxonomy of strategies provided These are:1)price and profit controls; 2) reimbursement system charges; 3) other fiscal measures; 4) quality measures. Pharmaceuticals policy has suffered from the pervasive misunderstanding that drugs are like any other commodity; resulting in policy makers viewing pharmaceuticals expenditures without thinking about drugs in their proper content of health care. The authors conclude by advocating a balanced approach to policymaking in a environment of rising pharmaceuticals costs.",
keywords = "Cost Control, Drug Costs, Economics, Pharmaceutical, Humans, Organizational Policy, Pharmacy Administration, Quality Assurance, Health Care, Reimbursement Mechanisms, Journal Article",
author = "Almarsd{\'o}ttir, {Anna Birna} and Traulsen, {Janine M}",
year = "2005",
month = "6",
doi = "10.1007/s11096-005-6953-6",
language = "English",
volume = "27",
pages = "144--8",
journal = "International Journal of Clinical Pharmacy",
issn = "2210-7703",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Cost-containment as part of pharmaceutical policy

AU - Almarsdóttir, Anna Birna

AU - Traulsen, Janine M

PY - 2005/6

Y1 - 2005/6

N2 - In this article the authors provide insight into the basis for price setting of medicines, the increasing pharmaceutical budgets in the past decades, and the measures governments and insures have taken to curb rising pharmaceutical costs. Four reasons are out lined for the fact that medicines are by some considered expensivey: 1) there are fundamental differences between medicines and other consumer products; 2) medicines are technology requiring an inordinate amount of research and development; 3) medicines are developed, manufactured, and distributed according to strict regulatory requirements; 4) medicines are most often selected by a physician for a specific patient and reimbursed in whole or in party by a third-party insurer or the state. Pharmaceuticals mean share of GDP has been 1.2% in OECD countries in recent decades. Pharmaceuticals accounted for 15.4% of total health expenditure, with public spending about half of this amount. Since 1970, the average share of GDP for pharmaceuticals in most countries has increased 1.5% more per year than GDP growth. Four types of strategies to curb rising Pharmaceuticals costs are described and a taxonomy of strategies provided These are:1)price and profit controls; 2) reimbursement system charges; 3) other fiscal measures; 4) quality measures. Pharmaceuticals policy has suffered from the pervasive misunderstanding that drugs are like any other commodity; resulting in policy makers viewing pharmaceuticals expenditures without thinking about drugs in their proper content of health care. The authors conclude by advocating a balanced approach to policymaking in a environment of rising pharmaceuticals costs.

AB - In this article the authors provide insight into the basis for price setting of medicines, the increasing pharmaceutical budgets in the past decades, and the measures governments and insures have taken to curb rising pharmaceutical costs. Four reasons are out lined for the fact that medicines are by some considered expensivey: 1) there are fundamental differences between medicines and other consumer products; 2) medicines are technology requiring an inordinate amount of research and development; 3) medicines are developed, manufactured, and distributed according to strict regulatory requirements; 4) medicines are most often selected by a physician for a specific patient and reimbursed in whole or in party by a third-party insurer or the state. Pharmaceuticals mean share of GDP has been 1.2% in OECD countries in recent decades. Pharmaceuticals accounted for 15.4% of total health expenditure, with public spending about half of this amount. Since 1970, the average share of GDP for pharmaceuticals in most countries has increased 1.5% more per year than GDP growth. Four types of strategies to curb rising Pharmaceuticals costs are described and a taxonomy of strategies provided These are:1)price and profit controls; 2) reimbursement system charges; 3) other fiscal measures; 4) quality measures. Pharmaceuticals policy has suffered from the pervasive misunderstanding that drugs are like any other commodity; resulting in policy makers viewing pharmaceuticals expenditures without thinking about drugs in their proper content of health care. The authors conclude by advocating a balanced approach to policymaking in a environment of rising pharmaceuticals costs.

KW - Cost Control

KW - Drug Costs

KW - Economics, Pharmaceutical

KW - Humans

KW - Organizational Policy

KW - Pharmacy Administration

KW - Quality Assurance, Health Care

KW - Reimbursement Mechanisms

KW - Journal Article

U2 - 10.1007/s11096-005-6953-6

DO - 10.1007/s11096-005-6953-6

M3 - Journal article

C2 - 16096878

VL - 27

SP - 144

EP - 148

JO - International Journal of Clinical Pharmacy

JF - International Journal of Clinical Pharmacy

SN - 2210-7703

IS - 3

ER -

ID: 170601760